Sanofi slowly exits Opella
Sanofi SA has become the latest pharma company to wind down its interest in consumer healthcare in order to focus on proprietary, prescription medicines. The French company is to sell a 50% controlling stake in Opella, its consumer business, to the US private equity group Clayton Dubilier & Rice. Under the deal, Sanofi will retain a significant interest in Opella, while increasing investment in new biopharma products and vaccines, according to Paul Hudson, the chief executive.